Study participants
V600E, RET, tumor, cancer
TUMOR, METASTATIC ADENOCARCINOMA, CANCER, NSCLC, ONCOLOGY
All subjects provided written informed consent. Main inclusion criteria were male or female subjects aged ≥20 years with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma NSCLC which was not amenable to curative surgery or radiation, with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, and meeting a clinical definition of acquired resistance to EGFR TKI.Key exclusion criteria included evidence of small cell histology, or combined small cell and non‐small cell histology in an original or screening tumor biopsy performed since progression; previously documented evidence of ALK fusion, ROS1 fusion, BRAF V600E mutation, rearranged during transfection (RET) fusion, human epidermal growth factor receptor 2 (HER2) mutation, or hepatocyte growth factor receptor (MET) exon 14 skipping mutation; treatment with any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI) within 14 days of the first dose of the current study treatment, or immune checkpoint inhibitor therapy within 30 days of first dose of the current study treatment; major surgery (excluding a vascular access procedure) within 4 weeks of the first dose of the current study treatment; radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks, or palliative radiation therapy within 2 weeks of the first dose of the current study treatment.